Insmed reported $57.18M in Selling and Administration Expenses for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Acelrx Pharmaceuticals ACRX:US $ 8.69M 1.05M
Alexion Pharmaceuticals ALXN:US $ 342.9M 101.5M
Alimera Sciences ALIM:US $ 8.69M 456K
Arena Pharmaceuticals ARNA:US $ 31.94M 2.48M
Biomarin Pharmaceutical BMRN:US $ 184.16M 9.84M
Cytokinetics CYTK:US $ 21.2M 5.6M
Dynavax Technologies DVAX:US $ 21.08M 862K
Flexion Therapeutics FLXN:US $ 27.41M 189K
Gilead Sciences GILD:US $ 1.34B 297M
Heron Therapeutics HRTX:US $ 33.16M 8.35M
Insmed INSM:US $ 57.18M 5.63M
Mirati Therapeutics MRTX:US $ 29.61M 1.26M
Novartis NVS:US 3.71B 190M
Regeneron Pharmaceuticals REGN:US $ 414.7M 9.1M
Sarepta Therapeutics SRPT:US $ 72.35M 1.22M
Seattle Genetics SGEN:US $ 165.13M 5.29M
Ultragenyx Pharmaceutical RARE:US $ 53.41M 152K
Vertex Pharmaceuticals VRTX:US $ 194.67M 2.59M